uniQure (NASDAQ:QURE) Upgraded to “Outperform” at Mizuho

uniQure (NASDAQ:QURE) was upgraded by equities research analysts at Mizuho from a “neutral” rating to an “outperform” rating in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $35.00 price objective on the biotechnology company’s stock, up from their prior price objective of $12.00. Mizuho’s target price suggests a potential upside of 91.68% from the stock’s previous close.

Several other equities research analysts have also issued reports on the company. William Blair reissued a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. The Goldman Sachs Group lowered their target price on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. HC Wainwright reissued a “buy” rating and set a $70.00 target price on shares of uniQure in a report on Tuesday. Barclays initiated coverage on shares of uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 price target on the stock. Finally, Chardan Capital boosted their price objective on shares of uniQure from $16.00 to $31.00 and gave the company a “buy” rating in a research report on Monday. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

uniQure Price Performance

QURE opened at $18.26 on Wednesday. The company has a 50-day moving average of $21.79 and a 200-day moving average of $29.66. The company has a market capitalization of $1.14 billion, a P/E ratio of -5.29 and a beta of 0.73. uniQure has a 1-year low of $7.76 and a 1-year high of $71.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. The business had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. Equities analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Insider Transactions at uniQure

In other news, Director Jack Kaye sold 6,390 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This represents a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Christian Klemt sold 12,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the transaction, the chief financial officer directly owned 226,581 shares in the company, valued at $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 81,399 shares of company stock worth $1,527,645 over the last quarter. Insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently bought and sold shares of QURE. Private Trust Co. NA bought a new position in uniQure in the 3rd quarter valued at about $28,000. Torren Management LLC acquired a new stake in shares of uniQure in the 4th quarter worth approximately $28,000. Jones Financial Companies Lllp boosted its holdings in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares in the last quarter. IFP Advisors Inc bought a new position in shares of uniQure in the fourth quarter valued at approximately $48,000. Finally, Smartleaf Asset Management LLC acquired a new position in shares of uniQure during the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Multiple broker upgrades and higher price targets — Chardan raised its target and called for strong appreciation, RBC upgraded to Outperform with a $35 target, and Wells Fargo moved the stock to Overweight with a $60 target. These upgrades lift near-term sentiment and institutional interest. Chardan Capital Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock
• Positive Sentiment: Regulatory backdrop improved — market reacted positively after reports of a senior FDA biologics official (CBER director) leaving, which traders interpreted as reducing near-term regulatory friction for AMT‑130 and other gene‑therapy approvals. That narrative helped lift biotech names including QURE. UniQure shares surge 26% on US FDA shakeup even as momentum tumbles: Will new leadership greenlight Huntington’s therapy?
• Positive Sentiment: Analyst reaffirmations and buy ratings (HC Wainwright kept a $70 target) support upside expectations and may sustain buying interest around upcoming catalysts. uniQure: Regulatory Shift and AMT-130 Outlook Drive Reaffirmed Buy Rating and $70 Target
• Neutral Sentiment: High short interest (≈21.2% of float) increases volatility: it can amplify rallies (short-covering) or exacerbate declines if negative news hits. This is a key liquidity/volatility metric to monitor.
• Neutral Sentiment: Wall Street focus ahead of binary drug catalysts — several analyst notes highlight asymmetric upside tied to AMT‑130 and other programs, but outcomes remain binary and trial/regulatory risk is high. uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
• Negative Sentiment: Multiple securities class action filings and law‑firm notices allege disclosures around AMT‑130 and related regulatory matters; several firms have issued investor alerts with an April 13 lead‑plaintiff deadline, creating legal overhang and potential liability risk. uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline
• Negative Sentiment: Regulatory accusations and investor‑rights firm claims — Hagens Berman and others highlight a public rebuke from federal health officials and allegations the company pushed “distorted” data for AMT‑130, which could materially damage credibility and regulatory prospects if substantiated. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.